KRAS G13D-IN-2

KRAS G13D-IN-2 (compound 8B) is a potent orally active KRAS G13D inhibitor with IC50 values of 1.95 μM (HCT-116G13D) and 2.16 μM (HCT-15G13D) . KRAS G13D-IN-2 induces G1-phase arrest and mitochondrial membrane depolarization. KRAS G13D-IN-2 induces senescence through CDK6/TWIST1 inhibition. KRAS G13D-IN-2 inhibits tumor growth in murine models. KRAS G13D-IN-2 can be used for KRASG13D-mutant colorectal cancer research[1].

Product Specifications

UNSPSC

12352211

Target

CDK; Mitochondrial Metabolism; Ras

Related Pathways

Cell Cycle/DNA Damage; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease

Field of Research

Cancer

Smiles

O[C@@H]1CC[C@@]2(C)[C@](CC[C@]3(C)[C@]2([H])CC=C4[C@@]3(C)CC[C@]5(C)[C@@]4([H])[C@@H](C)[C@H](C)CC5)([H])[C@@]1(C)NC(N[C@@H](CC(C)C)C(O)=O)=O

Molecular Formula

C36H60N2O4

Molecular Weight

584.87

References & Citations

[1]Qayum A, et al. Synthesis of β-boswellic acid-amino acid conjugates for targeting KRASG13D mutant colon cancer. Eur J Med Chem. 2026 Jan 15;302 (Pt 2) :118336.